J Korean Ophthalmol Soc > Volume 57(4); 2016 > Article
Journal of the Korean Ophthalmological Society 2016;57(4):582-587.
DOI: https://doi.org/10.3341/jkos.2016.57.4.582    Published online April 15, 2016.
Influence of Intravitreal Bevacizumab Injection on Formation of Collateral Vessels in Branch Retinal Vein Occlusion.
Yeng Woo Son, Seung Woo Lee
Department of Ophthalmology, Dongguk University College of Medicine, Gyeongju, Korea. jazzhanul@hanmail.net
망막분지정맥폐쇄에서 유리체강 내 베바시주맙 치료가 측부혈관 형성에 미치는 영향
동국대학교 의과대학 안과학교실
Correspondence:  Seung Woo Lee
Received: 27 February 2015   • Revised: 17 June 2015   • Accepted: 25 January 2016
To evaluate the influence of retinal collateral vessels in eyes with macular edema secondary to branch retinal vein occlusion (BRVO) treated with intravitreal bevacizumab (IVB). METHODS: We reviewed the medical records of patients with BRVO who were followed up for 12 months. To compare formations of collateral vessels, the patients were divided into 2 groups. The treatment group included 20 patients (20 eyes) treated with IVB, and the control group included 41 patients (41 eyes) without treatment. RESULTS: In the treatment group, the mean age was 58.4 ± 9.5 years. The average number of IVB injections performed during the 12 months was 4.5 ± 2.5 (range 2 to 8). After 12 months from diagnosis, 13 eyes (65%) presented with collateral vessels. In the control group, the mean age was 60.6 ± 9.3 years and 28 eyes (68.3%) presented with collateral vessel after 12 months. There was no difference in incidence of collateral vessel formation between the treatment group and the control group (p = 0.574). CONCLUSIONS: IVB does not influence the formation of retinal collateralization in eyes treated for macular edema secondary to BRVO.
Key Words: Bevacizumab;Collateral Vessels;Macular Edema;Retinal Vein Occlusion

Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2021 by Korean Ophthalmological Society. All rights reserved.

Developed in M2PI

Close layer
prev next